Jiaxuan Liu
Visting PhD Students
Research interest
Breast cancer precision medicine
Education background
PhD, Cancer Hospital, Peking Union Medical College
MSc, Cancer Hospital, Peking Union Medical College
2025 Spring
BSc, Queen Mary School (Joint program), Nanchang University & Queen Mary University of London
Email: jxjxjxliu@163.com
Publication
1. Liu J, Zhang P*, Xu B*, Li Q*; et al. Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. Int J Cancer. 2024;154(1):133-144.
2. He M#, Liu J#, Li Q*, Xu B*; et al. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast. 2023 Dec;72:103581.
3. Liu J#, He M#, Xu B*, Li Q*; et al. Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. BMC Cancer. 2024 Oct 18;24(1):1290.
4. Liu J#, Zhang J#, Shao B*, Li Q*; et al. Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. BMC Cancer. 2025 Jan 3;25(1):9.
5. Li Q, Liu J, Xu B*; et al. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nat Commun 2024;15(1):1015.